vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and FIRST MID BANCSHARES, INC. (FMBH). Click either name above to swap in a different company.
FIRST MID BANCSHARES, INC. is the larger business by last-quarter revenue ($88.2M vs $85.1M, roughly 1.0× 4D Molecular Therapeutics, Inc.). FIRST MID BANCSHARES, INC. runs the higher net margin — 26.8% vs 22.8%, a 4.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 5.0%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
FDMT vs FMBH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $88.2M |
| Net Profit | $19.4M | $23.7M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 34.0% |
| Net Margin | 22.8% | 26.8% |
| Revenue YoY | 8508900.0% | 3.4% |
| Net Profit YoY | 139.1% | 23.5% |
| EPS (diluted) | $0.43 | $0.98 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $88.2M | ||
| Q3 25 | $90.0K | $89.3M | ||
| Q2 25 | $15.0K | $87.5M | ||
| Q1 25 | $14.0K | $84.3M | ||
| Q4 24 | $1.0K | $85.3M | ||
| Q3 24 | $3.0K | $80.6M | ||
| Q2 24 | $5.0K | $79.2M | ||
| Q1 24 | $28.0K | $79.9M |
| Q4 25 | $19.4M | $23.7M | ||
| Q3 25 | $-56.9M | $22.5M | ||
| Q2 25 | $-54.7M | $23.4M | ||
| Q1 25 | $-48.0M | $22.2M | ||
| Q4 24 | — | $19.2M | ||
| Q3 24 | $-43.8M | $19.5M | ||
| Q2 24 | $-35.0M | $19.7M | ||
| Q1 24 | $-32.4M | $20.5M |
| Q4 25 | 17.3% | 34.0% | ||
| Q3 25 | -67983.3% | 32.2% | ||
| Q2 25 | -396373.3% | 34.4% | ||
| Q1 25 | -383007.1% | 33.4% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | -1704400.0% | 31.5% | ||
| Q2 24 | -849120.0% | 33.7% | ||
| Q1 24 | -136200.0% | 33.7% |
| Q4 25 | 22.8% | 26.8% | ||
| Q3 25 | -63195.6% | 25.2% | ||
| Q2 25 | -364386.7% | 26.8% | ||
| Q1 25 | -342657.1% | 26.3% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | -1461433.3% | 24.2% | ||
| Q2 24 | -699060.0% | 24.9% | ||
| Q1 24 | -115717.9% | 25.6% |
| Q4 25 | $0.43 | $0.98 | ||
| Q3 25 | $-1.01 | $0.94 | ||
| Q2 25 | $-0.98 | $0.98 | ||
| Q1 25 | $-0.86 | $0.93 | ||
| Q4 24 | — | $0.81 | ||
| Q3 24 | $-0.79 | $0.81 | ||
| Q2 24 | $-0.63 | $0.82 | ||
| Q1 24 | $-0.66 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | — |
| Total DebtLower is stronger | — | $354.5M |
| Stockholders' EquityBook value | $505.7M | $958.7M |
| Total Assets | $566.7M | $8.0B |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | — | ||
| Q3 25 | $305.1M | — | ||
| Q2 25 | $293.2M | — | ||
| Q1 25 | $321.4M | — | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | — | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | — | $354.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $505.7M | $958.7M | ||
| Q3 25 | $369.0M | $932.2M | ||
| Q2 25 | $420.9M | $894.1M | ||
| Q1 25 | $469.7M | $870.9M | ||
| Q4 24 | $510.6M | $846.4M | ||
| Q3 24 | $552.9M | $858.5M | ||
| Q2 24 | $588.3M | $813.6M | ||
| Q1 24 | $600.6M | $798.0M |
| Q4 25 | $566.7M | $8.0B | ||
| Q3 25 | $424.0M | $7.8B | ||
| Q2 25 | $473.6M | $7.7B | ||
| Q1 25 | $515.7M | $7.6B | ||
| Q4 24 | $560.4M | $7.5B | ||
| Q3 24 | $604.0M | $7.6B | ||
| Q2 24 | $620.1M | $7.6B | ||
| Q1 24 | $629.9M | $7.7B |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $130.9M |
| Free Cash FlowOCF − Capex | $28.5M | $124.0M |
| FCF MarginFCF / Revenue | 33.5% | 140.6% |
| Capex IntensityCapex / Revenue | 0.1% | 7.8% |
| Cash ConversionOCF / Net Profit | 1.47× | 5.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $207.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $130.9M | ||
| Q3 25 | $-46.5M | $33.0M | ||
| Q2 25 | $-43.4M | $7.7M | ||
| Q1 25 | $-47.8M | $47.9M | ||
| Q4 24 | $-134.6M | $124.4M | ||
| Q3 24 | $-29.4M | $33.1M | ||
| Q2 24 | $-30.2M | $24.0M | ||
| Q1 24 | $-29.1M | $29.0M |
| Q4 25 | $28.5M | $124.0M | ||
| Q3 25 | $-46.6M | $31.9M | ||
| Q2 25 | $-43.4M | $6.0M | ||
| Q1 25 | $-48.4M | $46.0M | ||
| Q4 24 | $-138.4M | $119.5M | ||
| Q3 24 | $-31.2M | $32.0M | ||
| Q2 24 | $-30.6M | $22.9M | ||
| Q1 24 | $-29.8M | $27.6M |
| Q4 25 | 33.5% | 140.6% | ||
| Q3 25 | -51765.6% | 35.8% | ||
| Q2 25 | -289620.0% | 6.8% | ||
| Q1 25 | -345635.7% | 54.5% | ||
| Q4 24 | -13837100.0% | 140.0% | ||
| Q3 24 | -1038966.7% | 39.7% | ||
| Q2 24 | -611840.0% | 28.9% | ||
| Q1 24 | -106421.4% | 34.5% |
| Q4 25 | 0.1% | 7.8% | ||
| Q3 25 | 101.1% | 1.2% | ||
| Q2 25 | 440.0% | 2.0% | ||
| Q1 25 | 4507.1% | 2.3% | ||
| Q4 24 | 378600.0% | 5.8% | ||
| Q3 24 | 59266.7% | 1.4% | ||
| Q2 24 | 6980.0% | 1.4% | ||
| Q1 24 | 2535.7% | 1.9% |
| Q4 25 | 1.47× | 5.53× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | — | 2.16× | ||
| Q4 24 | — | 6.49× | ||
| Q3 24 | — | 1.70× | ||
| Q2 24 | — | 1.21× | ||
| Q1 24 | — | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
